Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases

Sarah Y. Boostrom, David M. Nagorney, John H. Donohue, Scott Harmsen, Kristine Thomsen, Florencia Que, Michael Kendrick, Kaye M. Reid-Lombardo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%,63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)2003-2010
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume13
Issue number11
DOIs
StatePublished - 2009

Fingerprint

Disease-Free Survival
Neoplasm Metastasis
Drug Therapy
Survival
Neoadjuvant Therapy
Liver
Age Groups

Keywords

  • Neoadjuvant therapy. FOLFOX. Hepatectomy. Colorectal cancer metastases. Survival

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology
  • Medicine(all)

Cite this

Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases. / Boostrom, Sarah Y.; Nagorney, David M.; Donohue, John H.; Harmsen, Scott; Thomsen, Kristine; Que, Florencia; Kendrick, Michael; Reid-Lombardo, Kaye M.

In: Journal of Gastrointestinal Surgery, Vol. 13, No. 11, 2009, p. 2003-2010.

Research output: Contribution to journalArticle

Boostrom, Sarah Y. ; Nagorney, David M. ; Donohue, John H. ; Harmsen, Scott ; Thomsen, Kristine ; Que, Florencia ; Kendrick, Michael ; Reid-Lombardo, Kaye M. / Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases. In: Journal of Gastrointestinal Surgery. 2009 ; Vol. 13, No. 11. pp. 2003-2010.
@article{12a1a660ee854ed79bb3e62390809afe,
title = "Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases",
abstract = "Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58{\%} men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93{\%}, 62{\%}, and 51{\%}, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90{\%},63{\%}, and 45{\%}, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51{\%}, 20{\%}, and 20{\%}, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58{\%}, 32{\%}, and 32{\%} (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.",
keywords = "Neoadjuvant therapy. FOLFOX. Hepatectomy. Colorectal cancer metastases. Survival",
author = "Boostrom, {Sarah Y.} and Nagorney, {David M.} and Donohue, {John H.} and Scott Harmsen and Kristine Thomsen and Florencia Que and Michael Kendrick and Reid-Lombardo, {Kaye M.}",
year = "2009",
doi = "10.1007/s11605-009-1007-3",
language = "English (US)",
volume = "13",
pages = "2003--2010",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "11",

}

TY - JOUR

T1 - Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases

AU - Boostrom, Sarah Y.

AU - Nagorney, David M.

AU - Donohue, John H.

AU - Harmsen, Scott

AU - Thomsen, Kristine

AU - Que, Florencia

AU - Kendrick, Michael

AU - Reid-Lombardo, Kaye M.

PY - 2009

Y1 - 2009

N2 - Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%,63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.

AB - Study Aims To determine if neoadjuvant FOLFOX/FOLFIRI is associated with improved disease-free survival (DFS) or overall survival (OS) in patients with colorectal metastases (CRM) to the liver. Methods Ninety-nine patients (from 457 eligible) with CRM that underwent hepatic resection during 2000 to 2005 were included. Group 1 (n=44) patients received neoadjuvant FOLFOX/FOLFIRI, and Group 2 (n=55) did not receive neoadjuvant therapy. Results There were 58% men. The median age for Group 1 was 58 and Group 2, 64 (p=0.03). OS for Group 1 at 1, 3, and 5 years was 93%, 62%, and 51%, respectively, with a median OS of 5.8 years. In Group 2 survival at 1l, 3, and 5 years was 90%,63%, and 45%, respectively, with a median OS of 3.7 years (HR 1.06, p=0.87). The DFS for Group 1 at 1, 3, and 5 years was 51%, 20%, and 20%, with a median DFS of 1.1 years and Group 2 at 1, 3, and 5 years was 58%, 32%, and 32% (median DFS-1.2 years; HR=1.24, p=0.45). Conclusions Neoadjuvant FOLFOX/FOLFIRI was employed more frequently in younger patients with CRM; however, neoadjuvant chemotherapy for CRM was not significantly associated with an increase in OS or DFS, despite additional adjuvant therapy.

KW - Neoadjuvant therapy. FOLFOX. Hepatectomy. Colorectal cancer metastases. Survival

UR - http://www.scopus.com/inward/record.url?scp=77952993629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952993629&partnerID=8YFLogxK

U2 - 10.1007/s11605-009-1007-3

DO - 10.1007/s11605-009-1007-3

M3 - Article

VL - 13

SP - 2003

EP - 2010

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 11

ER -